carbamazepine

Overview

Carbamazepine is a widely used antiepileptic drug with additional clinical use in certain pain syndromes, including trigeminal neuralgia. Pharmacologically, it is valued for its ability to reduce abnormal neuronal excitability, which underlies its seizure-suppressing and analgesic effects. In biomedical research, carbamazepine is often studied as a model poorly soluble, modified-release oral drug, because its dissolution behavior can strongly influence formulation performance and drug exposure.

Beyond its established therapeutic role, carbamazepine is also used in mechanistic studies of neurobiology and drug delivery. Recent work has examined how it affects inflammatory and signaling pathways in the nervous system, including nitric oxide and hydrogen sulfide-related processes, while formulation studies have focused on improving its release from tablets and alternative dosage forms. These investigations reflect both its clinical importance and the challenges posed by its physicochemical properties.

Focus of Latest Publications

Recent publications have examined carbamazepine in several formulation and therapeutic contexts, with a strong emphasis on oral drug delivery performance. In tablet design studies, carbamazepine was included among a set of active pharmaceutical ingredients used to test predictive models for compressibility and compactibility, where its mechanical behavior contributed to the development of digital tools for estimating tablet solid fraction and tensile strength in binary and ternary mixtures. The approach was reported to predict solid fractions within ±5% of measured values, while tensile strength predictions varied more widely depending on formulation and compaction pressure.

Carbamazepine was also investigated in modified-release systems under conditions relevant to alcohol exposure. In hydroethanolic media, its release behavior changed because increased solubility shifted the mechanism from erosion-dominated to diffusion-dominated release. Similar release profiles across aqueous and ethanol-containing media were achieved only with hydrophilic polymers that had relatively high erosion rates, highlighting the importance of matrix composition in preventing accelerated release.

Several studies focused on predictive dissolution and bioequivalence-oriented testing for carbamazepine formulations. A flow-through cell method using USP Apparatus 4 was developed for a modified-release carbamazepine product, with dissolution conditions optimized by experimental design and IVIVC-based analysis. The resulting model showed strong correlation with pharmacokinetic behavior, with an r2 of 0.9905 and low prediction errors for AUC0-t and Cmax, and it successfully distinguished immediate-release from modified-release formulations. This work supports the use of predictive in vitro methods for formulation optimization and generic development.

Carbamazepine was also evaluated in emerging dosage forms and delivery platforms. In semi-solid extrusion 3D printing, it was loaded into milk formula-based chewable pediatric dosage forms, where the printed matrix enhanced carbamazepine release relative to crystalline drug and supported dose-flexible, soft chewable constructs. In another study, porous silicon nanoparticles were used for co-delivery of carbamazepine and hydrogen gas; carbamazepine-loaded particles showed enhanced drug release but reduced hydrogen output, and tablet compression was limited by the poor compressibility of the nanoparticle powder. Beyond formulation science, carbamazepine was directly visualized in an epilepsy model as a modulator of brain hydrogen sulfide dynamics, where it downregulated H2S in association with suppressed seizures and anti-inflammatory effects.